thebench.bio #1 Ecosystem for the Bio-Tech Industry

Funding Daily Summary

Funding Daily Summary: What Happened on November 19, 2026

Seawolf launches with $100 million and Sanofi deal

The company is developing lipid nanoparticles to deliver DNA and potentially support repeat dosing.

  • Updated
  • Read from 1 article, 1 publication

Today in brief

Seawolf emerged from stealth with $100 million in seed and Series A financing, plus an upfront payment from Sanofi under a collaboration.1 Its TRIDENT platform packages therapeutic DNA with RNA that encodes a protein intended to help the DNA enter a cell’s nucleus.1

Seawolf pairs launch financing with Sanofi deal

Seawolf raised $100 million in seed and Series A financing and received an upfront payment from Sanofi under their collaboration.1 The company is developing TRIDENT to give RNA-based lipid nanoparticles the durability associated with viral gene therapies while retaining the potential for repeat dosing.1

The platform aims to limit immune responses that could restrict repeat dosing.1